Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: Lucky who wrote (545)	7/9/1998 7:39:00 PM
From: David K.	Read Replies (1) \| Respond to of 4028

CSI Expands Staff to Exploit Antisense Technology July 9, 1998 07:18 PM HOUSTON--(BUSINESS WIRE)--July 9, 1998--Cryogenic Solutions Inc CYGS named Laurence Mealey as Vice President for Commercial Development. "Mr. Mealey brings the kind of high level multinational corporate experience that we need to optimize the value of biotechnology as far reaching as the ssDNA expression vector promises to be." said Board Chairman, Dell Gibson. Laurence Mealey was born in England where he earned his BME and MBA degrees. He has over three decades experience as CEO, CFO or COO with such international companies as Gulf and Western, The Laird Group in London, and Inco of Canada. Using "hands on " experience, Mr. Mealey has enabled fledgling companies to realize their full market potential as well as improving efficiency and profitability of existing companies. His international successes have included activities in nearly every European country as well as Brazil, Mexico, Canada, and of course the US. In April 1997, CSI licensed technology and began perfecting the patent for their TeloVector(TM) designed to synthesize sequence specific single strands of DNA (ssDNA) in cells (in vivo) to repair telomere ends shortened during cell division (mitosis). The same basic technology promises to be the missing piece to the antisense efficacy puzzle, namely a dependable method of delivering the antisense molecules into the cells of living organisms where they can do their job of disabling or modifying the behavior of the rogue genes that cause many of our more common and devastating diseases including HIV, Herpes, Hepatitis C, and most kinds of Cancer. According to a March 96 analysis by "Scrip Reports", "By the year 2000 the total value of the market for antisense therapies is expected to be $1.1 billion. And this figure is expected to nearly double to $2.12 billion by the year 2005. " It was estimated that the figure will be many times higher when a dependable delivery mechanism is available. "Although the term 'antisense' is not a household word, it is well recognized in the realm of biotech companies exploring leading edge genetic therapies," said Mr. Mealey. "In my view, Antisense therapeutics is the singular most significant medical break through since the discovery of effective vaccines." Top